Crossover Dose Escalation Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of Single Doses of R1663, an Oral Factor Xa Inhibitor, in Healthy Male Volunteers.
Phase of Trial: Phase I
Latest Information Update: 19 Jun 2011
At a glance
- Drugs R 1663 (Primary)
- Indications Embolism and thrombosis; Haemorrhage
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 19 Jun 2011 New trial record